APA (7th ed.) Citation

F, B., L, F. D., C, G., S, F., CE, T., & M, N. (2022). Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis. Archives of gynecology and obstetrics, 306(2), 569. https://doi.org/10.1007/s00404-021-06390-3

Chicago Style (17th ed.) Citation

F, Barra, Ferro Desideri L, Gustavino C, Ferrero S, Traverso CE, and Nicolò M. "Concerns on Ranibizumab and Zoledronic Acid Safety for Experimentally Treating Women with Endometriosis." Archives of Gynecology and Obstetrics 306, no. 2 (2022): 569. https://doi.org/10.1007/s00404-021-06390-3.

MLA (9th ed.) Citation

F, Barra, et al. "Concerns on Ranibizumab and Zoledronic Acid Safety for Experimentally Treating Women with Endometriosis." Archives of Gynecology and Obstetrics, vol. 306, no. 2, 2022, p. 569, https://doi.org/10.1007/s00404-021-06390-3.